From Jab to Pills: Novo Nordisk, Eli Lilly set to take obesity drug battle to India

India’s obesity drug market is set for a new phase as Novo Nordisk’s oral Wegovy and Eli Lilly’s oral GLP-1 orforglipron are expected to launch in the first half of 2027. Industry sources said both have been submitted to Indian regulators, potentially expanding demand beyond injectable treatments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CkebFWv
via IFTTT

Read More

Lord’s Mark secures MHRA registration for dialysis device, plans UK expansion

Lord's Mark Industries Limited has successfully secured regulatory registration from the MHRA for its innovative haemodialysis machine, paving the way for its expansion in the UK's healthcare technology sector. With plans to commence exports in January 2027 and potentially establish its own dialysis centres, this milestone signifies a crucial step towards creating a comprehensive renal-care ecosystem, manufactured by Renalyx Health Systems Pvt. Ltd. for both institutional and home usage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yfeC9vG
via IFTTT

Read More

ChrysCapital to take minority stake in Linux laboratories

Linux Laboratories has secured $70 million in equity funding from ChrysCapital and Tata Capital Healthcare Fund III. This investment involves both primary capital and a secondary purchase, marking Tata Capital Healthcare Fund II's full exit. The funding will help Linux deepen its presence in existing specialties and expand into new therapeutic areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RybAXgJ
via IFTTT

Read More

Sun Pharma plans $1 billion local debt sale for loan takeout, sources say

Sun Pharma is planning to raise about Rs 10,000 crore through rupee-denominated bonds to partly refinance a bridge loan used for its Organon acquisition, according to Reuters. The drugmaker is expected to issue two-, three- and four-year bonds as Indian companies increasingly turn to domestic debt amid high US borrowing costs and expectations of an RBI rate hike.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8rh4Cyg
via IFTTT

Read More

SC draws the line on Fortis audit, says no ‘fishing and roving’ probe into banks

The Supreme Court clarified the forensic audit's focus is on Fortis Healthcare Holdings Private Limited and the Singh Brothers. This audit is not a broad inquiry into the dealings of other banks. The court highlighted the audit relates specifically to transactions between FHHPL, FHL, and banks involved. The clarification came in response to a prior ruling by the Delhi High Court.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eLn10bd
via IFTTT

Read More

Kerala HC says exorbitant drug prices can trigger government intervention in patented medicines

The Kerala High Court ruled that government intervention is permissible for prohibitively priced patented medicines. The court directed the Centre to gather data on the affordability of specific life-saving drugs. This ruling addresses access issues for two breast cancer medications, abemaciclib and ribociclib. The decision empowers the government to consider invoking Section 100 of the Patents Act for affordable access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kNIEnjZ
via IFTTT

Read More

Sun Pharma signs major deal with LIB Therapeutics of US, gains access to $3.7-bn global market for bad cholesterol inhibitor PCSK9

Sun Pharma has signed an exclusive agreement with LIB Therapeutics for Lerodalcibep, a cholesterol-lowering medication. This deal covers all markets globally except for the United States and China. Lerodalcibep, a once-monthly PCSK9 inhibitor, will be marketed under the name Lyrokaul in Europe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YrEHkSp
via IFTTT

Read More